secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-124047
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie to acquire Cerevel Therapeutics for $45/share (~$8.7B equity value)
--------------------------------------------------------------------------

- Transaction valued at $45.00 per Cerevel share, total equity ~$8.7B; approved by both boards.
- Cerevel's late-stage asset emraclidine is a potential best-in-class antipsychotic for schizophrenia.
- Deal expected to close mid-2024, subject to Cerevel shareholder vote, regulatory approvals, and customary conditions.
- Acquisition adds multiple clinical assets: tavapadon (Parkinson's), CVL-354 (MDD), darigabat (epilepsy/panic).
- AbbVie expects transaction to be accretive to adjusted diluted EPS beginning in 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/0001104659-23-124047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000110465923124047/tm2332303d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-124047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer